The Colorectal Cancer Screening Market is projected to reach $9.73 billion by 2033 from $1.93 billion in 2022, growing at a CAGR of 15.94% during the forecast period 2023-2033. 

The growth in the global colorectal cancer screening market is expected to be driven by the rising incidence of colorectal cancer and the increasing financial burden on healthcare, advances in genomics and molecular diagnostics, and the growing demand for non-invasive testing for colorectal cancer.

The colorectal cancer screening market is in the developing phase. Government-sponsored population-wide screening programs and the growing burden of colorectal cancer and patient awareness in emerging economies can be some of the major opportunities in the global colorectal cancer screening market. Furthermore, some of the key trends going on in the market are the rise of at-home and multimodal approaches for colorectal cancer screening.

Market Segmentation:

Segmentation 1: by Technique

Segmentation 2: by Sample Type

Segmentation 3: by Region

Key Companies Profiled

•   Clinical Genomics Technologies Pty Ltd.
  •    Danaher Corporation
  •    DiaCarta, Inc.
  •    Eiken Chemical Co., Ltd.
  •    Epigenomics AG
  •    Exact Sciences Corporation
  •    Freenome Holdings, Inc.
  •    Guardant Health, Inc.
  •    Lepu Medical Technology (Beijing) Co., Ltd.
  •    Mainz Biomed NV
  •    New Horizon Health
  •    Novigenix SA
  •    Prenetics Global Limited
  •    Quest Diagnostics
  •    QuidelOrtho Corporation

Take Action: Gain Valuable Insights into the Rising Investments and Growth of Colorectal Cancer Screening Market – Download Our Free Sample Report Now!

Get Flat 15% Discount on Report Purchase - Use Code : SUMMER23

How can this report add value to an organization?

Product/Innovation Strategy: The techniques segment helps the reader understand the different types of techniques being used in colorectal screening. Moreover, the study provides the reader with a detailed understanding of colorectal cancer screening market based on techniques such as fecal occult blood test (FOBT) and fecal immunochemical test (FIT), and molecular testing.

Growth/Marketing Strategy: The global colorectal cancer screening market has seen major development by key players operating in the market, such as business expansions, partnerships, collaborations, mergers and acquisitions, product launches, and funding activities. Partnerships, alliances, and business expansions accounted for the maximum number of key developments in the global colorectal cancer screening market, followed by funding activities.

Competitive Strategy: Key players in the global colorectal cancer screening market analyzed and profiled in the study involve players that offer colorectal cancer screening products and services. Moreover, comprehensive competitive strategies, such as creating awareness campaigns for early detection of colorectal cancer by entering into collaborations with governing bodies. These scenarios will aid the reader in understanding the untapped revenue pockets in the market.